Table 1.

Characteristics of the treatment for the patient's 12 consecutive miscarriages

No.	Date	hCGa	GSb	Yolk sac	Embryo	FHMc	D&C	Cromd	LDAe	Heparin	PSLf	IVIGg	IMh	Miscarriage
1	2007/11	+	Yes	No	No	No	No	No	No	No	No	No	No	Yes
2	2008/02	+	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	Yes
3	2008/09	+	No	No	No	No	No	No	Yes	No	No	No	No	Yes
4	2009/03	+	Yes	No	No	No	Yes	No	Yes	No	No	No	No	Yes
5	2009/11	+	Yes	Yes	Yes	Yes	Yes	46, XX	Yes	No	No	No	No	Yes
6	2010/05	+	Yes	No	No	No	No	No	Yes	Yesi	No	No	No	Yes
7	2011/06	+	Yes	No	No	No	No	No	Yes	Yesj	No	No	No	Yes
8	2011/09	+	Yes	No	No	No	Yes	46, XY	Yes	Yesk	No	No	No	Yes
9	2012/05	+	No	No	No	No	No	No	Yes	No	No	No	No	Yes
10	2012/09	+	Yes	Yes	CRL:16l	Yes	Yes	46, XY	Yes	Yesk	5 mg	No	No	Yes
11	2014/04	+	Yes	Yes	CRL:15l	Yes	Yes	47, XX+22	Yes	Yesk	5 mg	Yes	No	Yes
12	2014/09	+	Yes	Yes	Yes	Yes	Yes	46, XX	Yes	Yesk	No	No	1 mg	Yes
13	2015/02	+	Yes	Yes	Yes	Yes	No	No	No	No	No	No	2 mg	No

^ahCG, the confirmation of serum human chorionic gonadotropin; ^bThe presence of a gestational sac in the uterine cavity; ^cThe confirmation of fetal heart movement; ^dChromosomal analysis; ^eLow‐dose aspirin (81 mg/d); ^fPrednisolone administration; ^gi.v. immunoglobulin administration (1 g/kg/3 d); ^hAdministration of an immunosuppressive agent (tacrolimus, mg/d); ⁱHeparin (2500 IU/d); ^jHeparin (5000 IU/day); ^kHeparin (10 000 IU/d); ^lCRL: crown rump length (mm).